Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17053036 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL1982884 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL2095212 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL1983358 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL6983332 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL23654034 | 1.00 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL18428250 | 0.96 | NR1H2 (0.43) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL1135308 | 0.91 | GPR119 (0.39) | HSD17B10NR1H2NR1H3HPGD | |
| SCHEMBL3697263 | 0.91 | GPR119 (0.39) | HSD17B10NR1H2NR1H3HPGD | |
| SCHEMBL2411163 | 0.91 | GPR119 (0.39) | HSD17B10NR1H2NR1H3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796297-B2 | 4-substituted-2-amino-pyrimidine derivatives | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | HRH2, HRH4, HRH3 | HSD17B10 3863/4885SMN1; SMN2 2514/4885NR1H2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.